Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLD100 Dose-Titration in Pediatric ADHD
NCT02884544Phase 2Completed
- Sponsor
- Ironshore Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dextroamphetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Ironshore Pharmaceuticals. Started Aug 2016; status: completed.
02
Drugs
dextroamphetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02884544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02884544.